Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

Pharmacogenetics

Volumn 8, Issue 1, 1998, Pages 15-26

  Griese, Ernst Ulrich ^a   Zanger, Ulrich M ^a   Brudermanns, Ulrich ^a   Gaedigk, Andrea ^a   Mikus, Gerd ^a   Mörike, Klaus ^a   Stüven, Thomas ^a   Eichelbaum, Michel ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

CYP2D6; Drug metabolism; Genetic polymorphism; Pharmacogenetics

Indexed keywords

CYTOCHROME; CYTOCHROME P450; SPARTEINE;

ADULT; ALLELE; ARTICLE; CATALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; INDIVIDUALIZATION; MALE; METABOLIC CAPACITY; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; ALLELES; BASE SEQUENCE; CATALYSIS; CYTOCHROME P-450 CYP2D6; DNA PRIMERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; GERMANY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MULTIGENE FAMILY; MUTATION; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SPARTEINE;

EID: 0031884233     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199802000-00003     Document Type: Article

References (49)

1. Agúndez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a while population. Clin Pharm Ther 1995; 57, 265-269.
2. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994; 4, 75-81.
3. Bertilsson L, Dahl ML, Sjöqvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M. Molecular basis for rational megaprescribing in ultra rapid hydroxylators of debrisoquine. Lancet 1993; 341, 63.
4. Bock KW, Schrenk D, Froster A, Griese EU, Mörike K, Brockmeier D, Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-Glucuronosyltransferases in man using sparteine, caffeine and paracetamol as probes. Pharmacogenetics 1994; 4, 209-218.
5. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10, 545-558.
6. Broly F, Meyer UA. Debrisoquine oxidation polymorphism: phenotypic consequences of a 5-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 1995; 3, 125-150.
7. Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice JM, Boone P, Meyer UA. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 1995; 5, 575-584.
8. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36, 557-547.
9. Brosen K, Nielsen PN, Brusgaard K, Gram LF, Skjodt K. CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 1994; 47, 221-225.
10. Brudermanns U. Populationsgenetik von spartein. Dissertation thesis. University of Bonn, Bonn, Germany, 1993.
11. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharm Ther 1996; 60, 522-554.
12. Dahl ML, Johansson I, Palmertz MP. Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharm Ther 1992; 51, 12-17.
13. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274, 516-520.
14. Daly AK, Armstrong M, Monkman SC, Idle MK, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991; 1, 33-41.
15. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996a; 6, 193-201.
16. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen V.M. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996b; 6, 319-328.
17. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16, 183-187.
18. Eichelbaum M, Bertilsson L, Säwe J. Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharm Ther 1982; 31, 184-186.
19. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990; 46, 377-394.
20. Evans WE, Relling MV. Xba I 16-plus 9-kilobase DNA restriction frag-\ ments identify a mutant allele for debrisoquine hydroxylase: Report of a family study. Mol Pharmacol 1990; 37, 639-642.
21. Evert B, Griese EU, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn Schmiedebergs Arch Pharmacol 1994a; 350, 434-439.
22. Evert B, Griese EU, Eichelbaum M. Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics 1994b; 4, 271-274.
23. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991; 48, 943-950.
24. Heim MH, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele specific PCR amplification. Lancet 1990; 336, 529-532.
25. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90, 11825-11829.
26. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996; 6, 351-355.
27. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990; 265, 17209-17214.
28. 2+-chelate affinity purification, and characterization of solubility and aggregation. Arch Biochem Biophys 1995; 321, 277-288.
29. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez EJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45, 889-904.
30. Kroemer HK, Eichelbaum M. 'It's the genes, stupid'. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995; 56, 2285-2298.
31. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Letts 1996; 392, 50-34.
32. Lovlie R, Daly AK, Idle JR, Steen VM. Characterization of the 16 + 9 kb and 30+9 kb CYP2D6 Xba I haplotypes. Pharmacogenetics 1997; 7, 149-152.
33. Maghoub A, Idle JR, Dring LG, Lancester R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2, 584-586.
34. Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Boone P, Rroly F. A novel CYP2D6 allele with an abolished splice site recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 1995; 5, 305-311.
35. Marez D, Legrand M, Sabbagh N, Lo-Guidice JM, Boone P, Rroly F. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Hum Genet 1996; 97, 668-670.
36. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42, 713-719.
37. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37, 269-296.
38. Panserai S, Mura C, Gérard N, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R. An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype. Br J Clin Pharmacol 1995; 40, 361-367.
39. 226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. Pharmacogenetics 1996; 6, 269-272.
40. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60, 284-295.
41. Saxena R, Shaw GL, Reilling MV, Frame JN, Moir DT, Evans WE, Caporaso N, Weiffenbach B. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994; 3, 923-926.
42. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450db1 gene associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988; 85, 5240-5243.
43. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E. Relationship between plasma desipramine levels. CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997; 51, 395-398.
44. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5, 215-223.
45. Stüven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM. Rapid detection of CYP2D6 null-alleles by long distance and multiplex polymerase chain reaction. Pharmacogenetics 1996; 6, 417-421.
46. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ. Identification of a new variant CYP2D6 allele lacking codon encoding Lys-281; possible association with the poor metabolizer phenotype. Pharmacogenetics 1991; 1, 26-32.
47. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53, 410-418.
48. Yokota H, Tamura S, Furuya U, Kimura S, Watanabe M, Kanazawa I, Kondo I, Gonzalez FJ. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1995; 3, 256-263.
49. Zanger UM, Meyer UA. Absent, decreased, or variant P450db1 in livers with poor capacity for debrisoquine metabolism. In: Schuster, I, ed. Cytochrome P450: biochemistry and biophysics. London: Taylor and Francis, 1989; 568-571.